POLG1 p.R722H mutation associated with multiple mtDNA deletions and a neurological phenotype by Komulainen, Tuomas et al.
Komulainen et al. BMC Neurology 2010, 10:29
http://www.biomedcentral.com/1471-2377/10/29
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Komulainen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research article POLG1 p.R722H mutation associated with multiple 
mtDNA deletions and a neurological phenotype
Tuomas Komulainen1,6, Reetta Hinttala2,6, Mikko Kärppä2,6, Leila Pajunen3, Saara Finnilä2,6, Hannu Tuominen4, 
Heikki Rantala1, Ilmo Hassinen5, Kari Majamaa*2,6 and Johanna Uusimaa1,6
Abstract
Background: The c.2447G>A (p.R722H) mutation in the gene POLG1 of the catalytic subunit of human mitochondrial 
polymerase gamma has been previously found in a few occasions but its pathogenicity has remained uncertain. We set 
out to ascertain its contribution to neuromuscular disease.
Methods: Probands from two families with probable mitochondrial disease were examined clinically, muscle and 
buccal epithelial DNA were analyzed for mtDNA deletions, and the POLG1, POLG2, ANT1 and Twinkle genes were 
sequenced.
Results: An adult proband presented with progressive external ophthalmoplegia, sensorineural hearing impairment, 
diabetes mellitus, dysphagia, a limb myopathy and dementia. Brain MRI showed central and cortical atrophy, and 18F-
deoxyglucose PET revealed reduced glucose uptake. Histochemical analysis of muscle disclosed ragged red fibers and 
cytochrome c oxidase-negative fibers. Electron microscopy showed subsarcolemmal aggregates of morphologically 
normal mitochondria. Multiple mtDNA deletions were found in the muscle, and sequencing of the POLG1 gene 
revealed a homozygous c.2447G>A (p.R722H) mutation. His two siblings were also homozygous with respect to the 
p.R722H mutation and presented with dementia and sensorineural hearing impairment. In another family the p.R722H 
mutation was found as compound heterozygosity with the common p.W748S mutation in two siblings with mental 
retardation, ptosis, epilepsy and psychiatric symptoms. The estimated carrier frequency of the p.R722H mutation was 
1:135 in the Finnish population. No mutations in POLG2, ANT1 and Twinkle genes were found. Analysis of the POLG1 
sequence by homology modeling supported the notion that the p.R722H mutation is pathogenic.
Conclusions: The recessive c.2447G>A (p.R722H) mutation in the linker region of the POLG1 gene is pathogenic for 
multiple mtDNA deletions in muscle and is associated with a late-onset neurological phenotype as a homozygous 
state. The onset of the disease can be earlier in compound heterozygotes.
Background
DNA polymerase γ (pol γ) is the only polymerase respon-
sible for the synthesis and repair of mitochondrial DNA
in mammalian cells [1,2]. The human mitochondrial
DNA polymerase is a 195 kDa heterotrimer consisting of
a 140 kDa catalytic subunit (pol γA) and two identical 55
kDa accessory subunits (pol γB) [3]. The C-terminus of
the catalytic subunit PolγA is the pol domain, which is
responsible for the polymerase function, while the N-ter-
minus is responsible for exonuclease activity and proof-
reading of the mitochondrial DNA (mtDNA). The linker
mediates a focal contact with the dimeric accessory sub-
unit [4]. PolγA is encoded by the POLG1  gene [Ref-
Seq:NM_002693].
Numerous mutations in the POLG1  have been
described recently, with various clinical presentations
[5,6] including autosomal dominant and autosomal reces-
sive familial external ophthalmoplegia (PEO) [7-10],
autosomal recessive sensory ataxic neuropathy with dys-
arthria and ophthalmoplegia (SANDO) [11], a mixed sen-
s o r y  a n d  c e r e b e l l a r  a t a x i c  s y n d r o m e  w i t h  e p i l e p s y
[12,13], parkinsonism [14,15] and Alpers' hepatocerebral
syndrome [16-19]. Other conditions associated with
POLG1  mutations include male subfertility, premature
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menopause and cataracts [15,20]. POLG1 mutations can
cause deletions or depletion in mtDNA [16,21-23].
We studied here the molecular etiology of a clinically
probable mitochondrial disease in five patients from two
Finnish families. In one family (Family A), an adult
patient presented with progressive external ophthal-
moplegia, sensorineural hearing impairment, diabetes
mellitus and dementia. In the other family (Family B), a
child presented with mental retardation, ptosis, epilepsy
and psychiatric problems.
Methods
Patients
Patient A1 is an 83-year-old man with sensorineural
hearing impairment, type 2 diabetes mellitus, dysphagia
and external ophthalmoplegia. A hearing aid had been
provided at age 72 years. At age 77 years, MMSE score
was 19 and a neuropsychological examination revealed a
mixed-type dementia. Neurological examination at age
83 years revealed external ophthalmoplegia and bilateral
ptosis. Tendon reflexes in the lower limbs were absent
and muscles were scanty, but muscle strength was nor-
mal. The MMSE score was 8. His ambulatory capacity
was normal, but he needed help in most of his daily activ-
ities due to dementia.
Laboratory investigations including blood lactate, pyru-
vate and creatine kinase were normal, as were the EEG
recording and electrophysiological examination of the
peripheral nerves. Brain MRI demonstrated moderate
cortical and central atrophy (Figure 1), including hip-
pocampal atrophy. Periventricular hyperintensities and a
left basal ganglia infarct were also found. PET performed
with 18F-deoxyglucose (FDG-PET) showed a reduction in
glucose uptake in the frontal, frontotemporal and fron-
toparietal regions (data not shown). Atrophic angular,
mostly type 2 muscle fibers were seen in a histological
examination of the left quadriceps muscle. Histochemical
analysis disclosed ragged red fibers and cytochrome oxi-
dase-negative fibers. Electron microscopy showed sub-
sarcolemmal aggregates of morphologically normal
mitochondria (Table 1).
Patient A2 is the younger sister of patient A1. She is a
78-year-old woman with a history of hypertension, sen-
sorineural hearing impairment requiring a hearing aid,
hypercholesterolemia, bilateral cataract and chronic gas-
tritis. She had been complaining of occasional headaches
since the age of 30 years. A neurological examination had
been performed at age 72 years on account of memory
impairment. There were no focal findings in the neuro-
logical examination. Brain CT revealed cortical atrophy
and one frontal lacunar infarct. The MMSE score was 26
and the score declined to 20 during the three subsequent
years. Her dementia, which involved behavioural changes
including aggressive symptoms and paranoid delusions,
was regarded as being of an Alzheimer-like type, and cho-
linergic therapy was introduced. Blood lactate was
slightly elevated (2.6 mmol/l, normal range 0.33-1.33
mmol/l), but blood pyruvate was normal (71 μmol/l, nor-
mal range 30-80 μmol/l), so that the lactate-pyruvate
ratio was increased (37, normal < 20). The remaining lab-
oratory tests were normal.
Patient A3 is the elder sister of patient A1. She is an 86
year-old woman with a clinical history of hypertension,
type 2 diabetes mellitus, sensorineural hearing impair-
ment, osteoarthritis, hypercholesterolemia and coronary
heart disease. She had a mild left motor hemiparesis at
the age of 74 years due to a lacunar brain infarct. Memory
impairment appeared and mild dementia was diagnosed
by a general practitioner, with CERAD and an MMSE
score of 22. There were no focal neurological signs except
for an absence of tendon reflexes. Brain CT revealed lacu-
nar changes in the right hemisphere but no atrophic find-
ings.
Patient B1 is the first child of healthy non-consanguine-
ous parents. She was born after an uncomplicated full-
term pregnancy and normal delivery. The perinatal
period was uneventful and control examinations in early
childhood did not reveal any abnormalities in psychomo-
tor development, growth or hearing except for slight
visual impairment. Learning difficulties were noticed
Table 1: Summary of the histological and histochemical 
findings of the muscle biopsy of patient A1.
Histological findings Light microsopy: Atrophic, 
angular muscle fibers
Electron microscopy: 
subsarcolemmal aggregates, 
morphologically normal 
mitochondria
Histochemical findings Ragged red fibers
Cytochrome c oxidase 
negative fibers
Figure 1 The brain MRI of patient A1. Axial (A) and coronal (B) MRI 
images of the brain of patient A1 demonstrate moderate central and 
cortical atrophy.Komulainen et al. BMC Neurology 2010, 10:29
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after attending school for some time and she was trans-
ferred to a special class for children with learning disabil-
ities. Seizures occurred at age 11 years, and focal
generalized epilepsy was diagnosed. Her EEG was abnor-
mal, showing focal bilateral frontotemporal irritation
with secondary generalization, but a brain CT was nor-
mal. No local neurological defects were found in the fol-
low-up clinical examination except for mild bilateral
ptosis. Pubertal development was normal and she has
normal menstruations. However, she gradually developed
behavioral and psychiatric problems, including depres-
sion, aggressivity and suicidality and had some psychotic
episodes needing hospitalization. She has no somatic
health problems except for occasional cardiac arrhythmia
and mild obesity. At present she is a 22-year-old woman
learning to live independently, but still needs support in
her daily life due to mild mental retardation and some
behavioral problems.
Patient B2 is the younger sister of patient B1. She was
born after a normal full-term pregnancy and delivery.
Early psychomotor development was normal, but mild
mental retardation was diagnosed before school age. She
attended a special school for children with learning dis-
abilities. Her pubertal development was normal, but she
is mildly obese and has a mild bilateral ptosis. Like her
elder sister, she has psychiatric problems, including
depression, aggressivity and suicidality. At present she is a
17-year-old young woman living in a residential school
for people with learning disabilities.
Clinical evaluation
Patients A1, A3, B1 and B2 were evaluated clinically by
means of a neurologic examination, laboratory tests and
long PCR of buccal DNA for possible mtDNA deletions.
The medical charts of patient A2 were reviewed. Four-
teen members of family A (Figure 2) were interviewed
using a questionnaire.
Molecular methods
Total genomic DNA was extracted from blood, muscle
and buccal smear samples using the standard sodium
dodecyl sulphate-proteinase K method or a QIAamp
Blood Kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions.
Detection of mtDNA deletions
MtDNA deletions were analyzed by long PCR (XL-PCR)
carried out using the Expand Long Template PCR System
kit (Boehringer Mannheim, Mannheim, Germany) as
described earlier [24].
Analysis of the POLG1, POLG2, ANT1 and Twinkle genes
Blood DNA was used as a template to amplify and
sequence the 23 coding exons of the POLG1 gene [Ref-
Seq:NM_002693] in the probands (patients A1 and B1) by
automated sequencing (ABI PRISM™ 377 Sequencer)
using the Dye Terminator Cycle Sequencing Ready Kit
(Perkin Elmer, Foster City, CA, U.S.A.) after treatment
with exonuclease I and shrimp alkaline phosphatase. The
entire coding sequence of the POLG2, ANT1 and Twinkle
genes were also determined.
Southern blot analysis was carried out using a biotin-
labeled probe. Total genomic DNA extract was digested
with FastDigest PvuII (Fermentas, Burlington, ON, Can-
ada). The mtDNA probe was amplified with PCR
between nucleotide positions 15714 and 725 to cover the
D-loop area, which is rarely involved in mtDNA dele-
tions. PCR reaction included biotin-16-dUTP (Roche,
Mannheim, Germany). The nylon membrane filter (Milli-
pore, Billerica, ME, U.S.A.) was prehybridized, hybrid-
ized with the probe, washed and incubated with Odyssey
Blocking Buffer (LI-COR Biosciences, Lincoln, NE,
U.S.A.) and Streptavidin-IRDye 800CW conjugate (LI-
COR Biosciences). The blot was scanned with Odyssey
Infrared Imaging System (LI-COR Biosciences).
Sequence analysis and molecular modeling
Secondary structure of pol γA was analyzed with the
Jpred3 server [25]. Sequence alignment of DNA poly-
merase γA of Homo sapiens (human),  Pan troglodytes
(chimpanzee), Canis lupus familiaris (dog), Mus muscu-
lus (house mouse), Rattus norvegicus (rat), Gallus gallus
(chicken), Danio rerio (zebrafish) and Drosophila mela-
nogaster (fruit fly) was carried out with the ClustalW pro-
gram.
Molecular modeling of the wild-type or R722H muta-
tion-carrying DNA polymerase-γA protein was per-
formed with the Modeller (v. 8.2) [26] program by using
the 3-D structure of the Klenow fragment of Escherichia
coli DNA polymerase I (1kln.pdb) as a template, and the
results were visualized with the MOLMOL program [27].
Detection of the POLG1 c.2447G>A (p.R722H) mutation
The  POLG1  c.2447G>A (p.R722H) mutation was
detected by restriction fragment analysis using a mis-
match primer that creates a restriction site for MlsI
(BalII) in the presence of the mutation. The mismatch
primer was designed in a forward direction with the
sequence 5'-TGTGTGGCCCTCACAGACTGGCC-3'
(mismatch base underlined). The sequence of the reverse
primer was 5'-TCAGGTGTGTCACTCTGAAGG-3'.
Template DNA was amplified by PCR, digested and the
products electrophoresed on a 3% MetaPhor (Cambrex
Bio Science Rockland, Inc., Rockland, ME, U.S.A.) gel
stained with ethidium bromide. The wild-type allele
yields a 221-bp band and the mutant allele a 183-bp band.
Detection of the POLG1 c.2243G>C (p.W748S) mutation
Allele-specific amplification was used to verify the
c.2243G>C (p.W748S) mutation in the blood DNA ofKomulainen et al. BMC Neurology 2010, 10:29
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patients B1 and B2 and their mother. The primers, con-
taining a locked nucleic acid (LNA) nucleoside base at the
3 '  e n d  ( P r o l i g o  L L C ,  P a r i s ,  F r a n c e ) ,  w e r e  d e s i g n e d  t o
anneal with either the wild-type sequence or the
sequence containing the mutation [28]. The sequence of
the LNA Polg14F/G primer was 5'-GGACATCCCTG-
GCTGCT+G-3' and of the LNA Polg14F/C 5'-GGA-
CATCCCTGGCTGCT+C-3'. The sequence of the
reverse primer was 5'-TCAGGTGTGTCACTCT-
GAAGG-3'.
Ethical considerations
The study protocol has been approved by Ethical Com-
mittee of Faculty of Medicine, University of Oulu and is
in compliance with the Helsinki Declaration. Written
informed consent is given by all patients or their surro-
gates prior to the study.
Results
Clinical findings
Clinical examination of patient A1 and patient A3 and the
review of the medical files of patient A2 revealed demen-
tia, sensorineural hearing impairment, progressive exter-
nal ophthalmoplegia and ptosis. The blood lactate/
pyruvate ratio was elevated in patient A2, but not in
patients A1 and A3, and the cerebral glucose metabolism
of patient A1 was reduced to 20-30%. The brain MRI of
patient A1 (Figure 1) showed moderate central and corti-
cal atrophy, while that of patient A2 revealed cortical
atrophy and one frontal lacunar infarct. A summary of
the medical histories of ten POLG1 p.R722H mutation
carriers, five deceased individuals and four non-carriers
in the family A is presented in Table 2.
Patient B1 presented with mental retardation, psychiat-
ric symptoms, mild bilateral ptosis and epilepsy, while her
sister (patient B2) had mental retardation, psychiatric
symptoms and mild bilateral ptosis, but no epilepsy.
Their mother had a history of mitral valve insufficiency,
which was operated on about three years ago, chronic
atrial fibrillation, for which she receives permanent anti-
coagulant therapy, cognitive impairment and impaired
hearing, but no localizing neurological symptoms. Her
MMSE score was 27. The blood lactate/pyruvate ratios of
patients B1 and B2 and their mother were normal. Medi-
cal history of the father was not available.
Molecular genetics
Long PCR of the muscle DNA of patient A1 showed mul-
tiple mtDNA deletions (Figure 3), and subsequent
sequencing of the entire POLG1 gene revealed a homozy-
gous c.2447G>A (p.R722H) transition in exon 13. Long
PCR of the muscle of age-matched controls showed dele-
tions in minor extent, but no deletions were detected
with Southern blot analysis (Figure 4). The homozygous
POLG1 p.R722H mutation of patient A1 was also found
in patients A2 and A3 (Figure 5), but no mtDNA dele-
tions were detected in the buccal or blood DNA of these
patients (data not shown). Muscle DNA was not available
for analysis from patients A2 and A3. No mutations were
found in the POLG2, ANT1 and Twinkle genes analyzed
from blood DNA of patients A1 and A2.
A heterozygous p.R722H mutation was found in 10 out
o f  1 7  m e m b e r s  o f  f a m i l y  A ,  a n d  f o u r  m e m b e r s  w e r e
Figure 2 Pedigree of family A. Fully shaded squares (men) and circles (women) denote homozygous c.2447G>A (p.R722H) mutations in the POLG1 
gene and half-shaded symbols heterozygosity.Komulainen et al. BMC Neurology 2010, 10:29
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homozygous with respect to the wild type (Figure 2).
There were also five deceased individuals in this family
that could be evaluated. Subject A5 had been an obliga-
tory carrier and A21 and A22 had been carriers, or else
one of them could have had a homozygous mutation, and
therefore subject A4 could have been either a carrier or
non-carrier of the mutation.
Patient B1 and patient B2 were heterozygous with
respect to c.2447G>A (p.R722H) and, interestingly,
POLG1  sequencing also revealed the c.2243G>C
(p.W748S) mutation and p.E1143G polymorphism in
patient B1 (Figure 5 and 6). POLG1 of patient B2 was not
sequenced. Their mother harbored heterozygous
p.W748S (Figure 5 and 6), but no DNA was available for
analysis from the father or other relatives. Long PCR of
buccal DNA did not show any deletions in the mtDNA of
patient B1. Three samples from 403 anonymous blood
donors harbored the heterozygous c.2447G>A
(p.R722H), suggesting a carrier frequency of 1:135 in the
population.
Sequence analysis and molecular modeling
Although the p.R722H and p.W748S mutations analyzed
in this study are located in the spacer region of pol γA,
they occur in an evolutionally conserved domain as
depicted in Figure 7. The p.W748 is highly conserved, but
p.R722 is not so well conserved even amongst mammals.
The PredictProtein and Jpred3 programs do not predict
major changes in the secondary structure (data not
shown). The tertiary structure on the basis of crystal dif-
fractometric data for the A-type DNA polymerases is
known only for Escherichia coli POL1 Klenow fragment
and bacteriophage T7. Alignment of human pol γA with
E. coli Klenow fragment of pol 1 identifies a loosely
homologous 701-724 region of pol γA. The correspond-
ing region of pol 1 around p.R631 is situated in a crevice
Table 2: Summary of the medical histories of members of 
family A with p.R722H mutation in POLG1.
Family member 
code
Clinical manifestation
p.R722H 
homozygotes
Patient A1 Severe dementia, sensorineural hearing 
impairment, diabetes mellitus, PEO, 
dysphagia, neuropathic pain in the legs
Patient A2 Moderate dementia, sensorineural 
hearing impairment, occasional 
headaches, cataract
Patient A3 Mild dementia, sensorineural hearing 
impairment, diabetes mellitus, 
hypertension, coronary heart disease, 
areflexia due to diabetic neuropathy
Carriers of 
p.R722H
A7 Diabetes mellitus, hypothyreosis, 
cerebral infarction, hypertension, 
hypercholesterolemia, learning 
difficulties
A8 Transient hypertension, benign cardiac 
arrhythmias, fertility problems
A9 Hypothyreosis, gestational diabetes 
mellitus
A10 Mental retardation
A11 Premature puberty, short stature, fertility 
problems, gestational diabetes mellitus
A12 Tinnitus, benign cardiac arrhythmias
A15 Cataract, balance disturbances, retinal 
rupture, tinnitus, unilateral deafness
A16 Coronary heart disease, delayed puberty, 
sensorineural hearing loss
A19 Delayed puberty, hypogonadism, 
transient vertigo, visual field defect
A20 Healthy
Deceased 
individuals of 
unknown 
mutation status
A4 Dementia, coronary heart disease, 
diabetes mellitus, rheumatoid arthritis, 
operated for colon cancer
A5 Diabetes mellitus, bradycardia, 
sensorineural hearing loss, coronary 
heart disease
A6 Psychiatric problems, sudden death 
from intracerebral haemorrhage
A21 Impaired memory, sudden death from 
cerebral infarct
A22 Dementia, hemiplegia progressing to 
diplegia, diabetes mellitus
Non-carriers
A13 Hypertension, distal sensory impairment 
in the hand
A14 Hypertension
A17 Unilateral hearing loss due to chronic 
secretory otitis, benign cardiac 
arrhythmia
A18 Healthy
Table 2: Summary of the medical histories of members of 
family A with p.R722H mutation in POLG1. (Continued)Komulainen et al. BMC Neurology 2010, 10:29
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being in close interaction of DNA strand in the co-crys-
tallized 1kln.pdb. This region was used as template for
homology modeling of pol γA. This puts the p.R722H
mutation in a helical region and the p.W748S in a more
flexible coil region without major effect on the secondary
or tertiary structure (Figure 8).
Discussion
Heterozygous  POLG1  p.R722H mutations have previ-
ously been reported in two patients with Parkinson's dis-
ease and in one control, with no difference in mutation
frequencies between these groups [14]. In our study,
patient A1 with the homozygous POLG1 p.R722H muta-
tion presented with dementia and sensorineural hearing
impairment together with progressive external ophthal-
moplegia, diabetes mellitus, dysphagia and neuropathic
pain in legs. Long PCR and Southern blotting revealed
multiple mtDNA deletions (Figure 3 and 4), which have
also been reported to be caused by several other POLG1
mutations [7,12,13]. Long PCR of the muscle DNA of
Figure 3 Long PCR of muscle DNA from patient A1 with POLG1 
p.R722H mutation. Lane 1, 1 kb ladder; lane 2, control muscle DNA, 
age 80 years; lane 3, control muscle DNA, age 89 years; lane 4, control 
muscle DNA, age 86 years; lane 5, control muscle DNA, age 75 years; 
lane 6, muscle DNA from patient A1, showing multiple mtDNA dele-
tions; lane 7, λ mix ladder.
Figure 4 Southern blot analysis of muscle DNA from patient A1. 
Lane 1, Biotin-labeled Lambda DNA/EcoR1 + HindIII ladder; lane 2, con-
trol muscle DNA, age 80 years; lane 3, control muscle DNA, age 89 
years; lane 4, patient A1.
Figure 5 Detection of the c.2447G>A (p.R722H) mutation in the 
POLG1 gene. POLG1 p.R722H mutation was detected from blood sam-
ples by restriction fragment analysis using the MlsI (BalII) enzyme. The 
183 bp fragment is visible in the case of the c.2447G>A (p.R722H) allele 
and the 221 bp fragment in the case of the wild-type allele. Lane 1, 100 
bp ladder; lane 2, Patient A1; lane 3, Patient A2; lane 4, Patient A3; lane 
5, Patient B1; lane 6, Patient B2; lane 7, Mother of patients B1 and B2.Komulainen et al. BMC Neurology 2010, 10:29
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healthy control samples showed also accumulation of
mtDNA deletions, but in obviously minor extent. These
deletions are likely due to the aging process and the pat-
tern of deletions is different from the deletions of the
patient A1. Long PCR did not show any intact mtDNA in
control samples as this method favors the amplification of
shorter DNA fragments. On the other hand, Southern
blot analysis showed the intact mtDNA, but did not
detect deletions in the muscle DNA of control samples.
This combination of multiple mtDNA deletions, multi-
ple neurological and endocrinological symptoms and his-
tochemical findings, including ragged red fibers and
COX-negative muscle fibers, suggests a mitochondrial
origin for the disease. The clinical features also resemble
those reported to be typical of POLG1 mutations [3,5,6].
It has been shown in a large cohort of POLG1 patients
that ptosis and PEO usually presented in teenage years or
adult life and additional features included a limb myopa-
thy, ataxia, a peripheral neuropathy or dysphagia, diabe-
tes, deafness and dementia [5]. Our patient A1
manifested with all these typical features associated with
POLG1 mutations. Two sisters of patient A1 also had the
homozygous p.R722H mutation and both presented with
dementia and sensorineural hearing impairment. Thus,
dementia and sensorineural hearing impairment segre-
gated consistently with the mutation.
We also described the compound POLG1 p.R722H +
p.W748S mutations in two siblings with mental retarda-
tion. The spectrum of clinical findings caused by the
p.W748S mutation is wide, and it has been found as a
heterozygous mutation compounded with other
heterozygous POLG1 mutations [5,13,18,29]. Mitochon-
Figure 6 Detection of the c.2243G>C (p.W748S) mutation in the POLG1 gene. POLG1 p.W748S mutation was detected from blood and buccal 
smear samples by LNA-primers. Lanes 2-9 were obtained with the Polg14F/C primer, showing one 140 bp band in the case of the mutation, and lanes 
10-17 with the Polg14F/G primer, showing a 140 bp band in the case of the wild-type. Lane 1, 100 bp ladder; lane 2, wild-type control; lane 3, positive 
mutation control; lane 4, heterozygous p.W748S control sample; lane 5, blood sample from patient B1; lane 6, buccal smear sample from B1; lane 7, 
mother; lane 8, patient B2; lane 9, H2O; lane 10, wild-type control; lane 11, positive mutation control; lane 12, heterozygous p.W748S control sample; 
lane 13, blood sample from patient B1; lane 14, buccal smear sample from patient B1; lane 15, mother; lane 16, patient B2; lane 17, H2O; lane 18, 100 
bp ladder.
Figure 7 Sequence alignment of part of the spacer regions of DNA polymerase γA. The mutation sites p.R722H and p.W748S are marked with 
arrowheads. The sequences (and accession numbers) are: human [RefSeq:NP_001119603.1], Pan troglodytes [RefSeq:XP_523149.2], Canis familaris 
[RefSeq:XP_545850.2], Rattus Norwegicus [RefSeq:NP_445980.1], Mus musculus [GenBank:AAA98977.1], Gallus gallus [GenBank:AAC60018.1], Danio 
rerio [RefSeq:XP_001921130.1] Drosophila melanogaster [GenBank:AAF53338.1].Komulainen et al. BMC Neurology 2010, 10:29
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drial recessive ataxia syndrome (MIRAS) is typically
found in patients with homozygous or compound
heterozygous p.W748S POLG1  mutations who present
with adult or juvenile-onset ataxia combined with dysar-
thria, sensory neuropathy, late cognitive impairment,
oculomotor defects, myoclonus, tremor, psychiatric
symptoms and seizures [18,29]. The clinical features of
patient B1 and her sister (patient B2) are consistent with
the patients harboring compound linker region muta-
tions who have epilepsy, mental retardation and psychiat-
ric symptoms as their presenting features [13,18]. A
similar phenotype has also been associated with another
heterozygous linker area mutation p.G517V with multi-
ple endocrinopathy, basal lacunar infarcts, seizures,
headache and psychiatric disorders as presenting features
[30]. Recent observations have suggested a possible dom-
inant effect in p.W748S heterozygotes, since more severe
phenotypes and poorer survival have been observed in
patients with compound heterozygosity for POLG1
p.W748S compared with patients who are homozygous
for this mutation [18].
Both POLG1 mutations, p.R722H and p.W748S, are sit-
uated in the linker region which mediates interaction
between the polymerase and exonuclease domains, so
that mutations might lead to a significant reduction in the
enzyme activity in vitro [31]. In vitro studies have also
suggested that the p.A467T mutation leads to conforma-
tional changes in the catalytic subunit and disrupts bind-
ing of the accessory subunit [32]. The p.W748S mutation
alone has been shown to cause a catalytic defect involving
poor DNA synthesis and primer extension [33], which
suggests that the compound p.R722H + p.W748S muta-
tion in POLG1 may lead to dysfunction of the polymerase
by alteration of the linker region according to a similar
pattern. Although the 3-D structure of subunit-A of the
mitochondrial DNA polymerase from higher eukaryotes
is not known, the crystal structure of the Klenow frag-
ment (residues 324-928) of E. coli DNA polymerase I has
been obtained, even complexed with duplex DNA and at
3.2 Å resolution [34]. Beese et al. [34] propose that DNA
enters the polymerase site from the 3'-exonuclease
domain and bends into a cleft. There are a few arginine
residues in this cleft domain, and p.R631 in a region
which gives a loose match with the human sequence, and
its positively charged guanidinium group is in close con-
tact with the phosphodiester backbone of one of the DNA
strands [34]. Site-directed mutagenesis of E. coli Klenow
fragment has shown that a p.R631A mutation leads to a
slight decrease in fidelity of the polymerase reaction
although the effect was not statistically significant [35].
Although the p.R722 of the eukaryotes is not highly con-
served, t he pr esence of ar ginine in this r egion ma y be
important. The homologous p.R631 in E. coli is con-
served in the Pol I family and located in a domain, which
experiences conformational change upon DNA binding.
In higher eukaryotes the corresponding "spacer" region
shows a high degree of evolutional conservation, suggest-
ing that this region has functional significance. Site-
directed mutagenesis of Drosophila pol γA has indicated
that the linker domain is involved in DNA binding [36].
Loss of the positive charge of arginine in this region may
affect template binding and by this means alter its activity
or fidelity.
The carrier frequency of p.R722H was 1:135 being as
high as that reported for two other POLG1 mutations in
the Nordic countries. The carrier frequency of p.W748S
is 1:125 in Finland [29] and 1:100 in Norway [13,37],
while that of p.A467T is 1:200 in Sweden and in Norway.
Figure 8 Cartoon of a tentative structure of a segment of the spacer region of human pol γA. Stereo views of the region from residue #700 to 
#770 of the normal (red/gray) and p.R722H/p.W748S double mutant (blue) protein is shown. The structure was predicted with homology modeling 
by using 1kln.pdb as a template. p.R722 (red), p.W748 (red), p.H722 (blue) and p.S748 (blue) are highlighted.Komulainen et al. BMC Neurology 2010, 10:29
http://www.biomedcentral.com/1471-2377/10/29
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Conclusions
We found a pathogenic mutation p.R722H in POLG1 in
three siblings, who were homozygous for the mutation
and presented with a clinical phenotype suggesting a
mitochondrial disease. Interestingly, in another family
two children were compound heterozygotes with respect
to POLG1 p.R722H and p.W748S mutations. The chil-
dren had mental retardation, ptosis and epilepsy thus
resembling the clinical phenotype that has been
described in subjects with compound heterozygosity for
p.W748S and another POLG1 mutation.
Homology modeling and analysis of the E. coli pol 1
suggest that p.R722 may reside near enough the DNA-
binding site to influence the replication fidelity. Although
the conservation of p.R722 is not high, it resides in a
highly conserved region. The sequence stretch around
p.R722 has some homology with a region in pol 1 of E.
coli having several amino acid residues with charged side
chains probably involved in DNA binding.
We suggest that POLG1 p.R722H mutation causes a
late-onset neurological phenotype as a homozygous state,
whereas the onset of the disease can be earlier in patients
with compound heterozygosity for POLG1 p.R722H and
other pathogenic POLG1 mutations. Due to the high car-
rier frequency of POLG1 p.W748S and p.R722H muta-
tions further clinical evaluation of carriers and in vitro
functional studies of these mutationswill be worthwhile.
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